About This Video
Tryp Therapeutics' CEO James Kuo, MD is joined by his team as they open the day's trading session on December 18th, 2020. Tryp Therapeutics trades on the Canadian Securities Exchange under the symbol CSE:TRYP
Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and/or safety profiles for the treatment of rare diseases and other diseases with high unmet medical needs. Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN, program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders. Tryp’s lead PFN drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome estimated to affect more than 5 million people in the United States.
In addition to its PFN Program, Tryp is developing TRP-1001, an oral formulation of razoxane for the treatment of soft tissue sarcoma. Soft tissue sarcomas are a rare and diverse group of tumors that account for about 1% of all cancers in adults and 7% in children. Based on the prevalence of soft tissue sarcomas in the United States, Tryp believes it is a rare disease and that TRP-1001 should qualify for Orphan Drug status.
To learn more about Tryp Therapeutics visit https://thecse.com/en/listings/life-sciences/tryp-therapeutics-inc
Subscribe for more great CSE insights and interviews here: https://bit.ly/CSETVSubscribe
STAY CONNECTED WITH THE CSE
=============================
- PODCAST: https://blog.thecse.com/pe-podcasts/
- INSTAGRAM: https://www.instagram.com/canadianexchange/
- LINKEDIN: https://ca.linkedin.com/company/canadian-securities-exchange
- FACEBOOK: https://www.facebook.com/CanadianSecuritiesExchange/
- TWITTER: https://twitter.com/CSE_News
- BLOG: https://blog.thecse.com/
- WEBSITE: https://thecse.com/
MB012Q74JXOOQNB
Read the TranscriptAuto-generated by YouTube; names and terms may be misspelled.
five four four two
oh
More CSE Market Open
Ring the Bell for Financial Literacy 2026Oct 8, 2026

